GeneCentric Therapeutics: Funding, Investors & Team (Sep 2026)
GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
GeneCentric Therapeutics has raised $10.0M across 2 funding rounds on record, the most recent a Convertible Note of $2.5M announced in Sep 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GeneCentric Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
GeneCentric Therapeutics Funding Rounds
GeneCentric Therapeutics raised $7.5M in a Series B announced in Nov 2021.
10 months later, a Convertible Note of $2.5M was announced in Sep 2022.
GeneCentric Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
GeneCentric Therapeutics Funding Compared to Other Biotechnology Startups
GeneCentric Therapeutics' latest round of $2.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GeneCentric Therapeutics in Biotechnology and Durham
Companies Similar to GeneCentric Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
GeneCentric Therapeutics Funding FAQs
What does GeneCentric Therapeutics do?
GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.
How much funding has GeneCentric Therapeutics raised?
GeneCentric Therapeutics has raised $10.0M across 2 rounds on record. The most recent is a Convertible Note of $2.5M announced in Sep 2022.
When did GeneCentric Therapeutics last raise funding?
GeneCentric Therapeutics' most recent funding round on record is a Convertible Note of $2.5M, announced in Sep 2022.
Who is the CEO of GeneCentric Therapeutics?
Michael Milburn is listed as CEO at GeneCentric Therapeutics.
Where is GeneCentric Therapeutics headquartered?
GeneCentric Therapeutics is based in Durham, North Carolina, United States.
How many employees does GeneCentric Therapeutics have?
GeneCentric Therapeutics is in the 11-50 employee band.
How does GeneCentric Therapeutics' funding compare to other Biotechnology startups?
GeneCentric Therapeutics' latest round of $2.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's GeneCentric Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GeneCentric Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.